製薬とインテリジェンス : CI能力は製薬企業の研究開発に影響を与えるか(<特集>戦略的意志決定とインテリジェンス)
スポンサーリンク
概要
- 論文の詳細を見る
Competitive intelligence (CI) involves a systematic program to exploit external information for decision making and strategy and the competence of strategy development. CI is particularly important for knowledge-intensive industries, of which the pharmaceutical industry is a typical example. The present paper discusses the relative importance of R&D resources (personal and financial), CI competence, and intentionality of exploiting external resources as factors influencing the R&D capability of research-intensive pharmaceutical companies in Japan. Analysis showed that the CI competence is the most important factor for success: its importance is greater than that of the R&D resources, although the latter is generally accepted as the fundamental factor in the R&D capacity of businesses. Intentionality of exploiting external resources showed no correlation with R&D capability, presumably because this factor was evaluated by "constant" reference to other companies' patents, technical alliances, outsourcing, or cooperation with venture enterprises. This result should rather be interpreted as indicating that decision making on stereotypical criteria results in little value. The CI capability of a pharmaceutical company includes strategic collection, analysis and evaluation of information, development of an intelligence system, and implementation of corporate strategies. The task of the prime importance for the business is, therefore, to embody the external information collected and analyzed in the corporate strategy.
- 研究・技術計画学会の論文
- 2008-06-12